Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines

Cancer Letters

Volumn 135, Issue 2, 1999, Pages 171-180

  Shelley, M D ^a   Hartley, L ^a   Fish, R G ^a   Groundwater, P ^b   Morgan, J J G ^a   Mort, D ^a   Mason, M ^a   Evans, A ^c  

^a Velindre NHS Trust   (United Kingdom)

^b UNIVERSITY OF SUNDERLAND   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Cytotoxicity; Gossypol enantiomers; Gossypolone

Indexed keywords

BUSULFAN; CISPLATIN; DACARBAZINE; DAUNORUBICIN; GOSSYPOL; HYDROXYUREA; MELPHALAN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MELANOMA; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; GOSSYPOL; HUMANS; MUTAGENICITY TESTS; TUMOR CELLS, CULTURED;

EID: 0033065750     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00302-4     Document Type: Article

References (39)

1. Adams R., Geissman T.A., Edwards J.D. Gossypol, a pigment of cottonseed. Chem. Rev. 60:1960;555-574.
2. Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs. 38:1989;333-341.
3. Han M.L., Wang Y.F., Tang M.Y., Ge Q.S., Zhou L.F., Zhu P.D., Sun Y.T. Gossypol in the treatment of endometriosis and uterine myoma. Contraception Gynecol. Obstet. 16:1987;268-270.
4. Qian S.Z., Wang Z.G. Gossypol: A potential antifertility agent for males. Annu. Rev. Pharmacol. Toxicol. 24:1984;329-360.
5. Tuszynski G.P., Cossu G. Differential effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res. 44:1984;768-771.
6. Rao P.N., Wang Y., Lotzova E., Khan A.A., Rao S.P., Stephens C.L. Antitumor effects of gossypol on murine tumors. Cancer Chemother. Pharmacol. 15:1985;20-25.
7. Wu Y.W., Chik C.L., Knazek R.A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res. 49:1989;3754-3758.
8. Coyle T., Levante S., Shetler M., Winfield J. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumour cell lines. J. Neuro-Oncol. 19:1994;25-35.
9. Erukhimov L.S. Treatment of bladder tumours by gossypol and ionol in combination with surgical intervention. Vopr. Onkol. 12:1966;29-34.
10. Bushunow P., Reidenberg M., Winfield J., Lemke S., Himpler B., Coyle T. Gossypol treatment in recurrent adult malignant gliomas. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14:1995;A282.
11. Flack M.R., Pyle R.G., Mullen N.M., Lorenzo B., Wu Y.W., Knazek R.A., Nisula B.C., Reidenberg M.M. Oral gossypol in the treatment of metastatic adrenal cancer. J. Clin. Endocrinol. Metab. 76:1993;1019-1024.
12. Ligueros M., Jeoung D., Tang B., Hochhauser D., Reidenberg M.M., Sonenberg M. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br. J. Cancer. 76:1997;21-28.
13. 1) as inhibitors of canine prostate growth. FASEB J. 9:(4):1985;4813.
14. Shidaifat F., Canatan H., Kulp S.K., Sugimoto Y., Chang W.Y., Zhang Y., Brueggemeier R.W., Somers W.J., Lin Y.C. Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-β Cancer Lett. 107:1996;37.
15. 1-acetyltransferase in canine prostate epithelial cells. Biochem. Biophys. Res. Commun. 231:1997;383-388.
16. 14C-gossypol in swine. Toxicol. Appl. Pharmacol. 31:1975;32-46.
17. Band V., Hoffman A., Band B., Rhinehardt A.E., Knapp R.C., Matlin S.A., Anderson D.J. Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. Gynaecol. Oncol. 32:1989;273-277.
18. Joseph A.E., Matlin S.A., Knox P. Cytotoxicity of enantiomers of gossypol. Br. J. Cancer. 54:1986;511-513.
19. Wu D.F., Yu Y.W., Tang Z.M., Wang M.Z. Pharmacokinetics of (+)-, (+)-, and (-)-gossypol in humans and dogs. Clin. Pharmacol. Ther. 39:1986;613-618.
20. Tyson R. Custom synthesis and process development. Chem. Ind. 15:1988;118-122.
21. Twentyman P.R., Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer. 56:1987;279-285.
22. Ormerod M.G. Analysis of DNA. Ormerod M.G. Flow Cytometry: A Practical Approach. 1990;69 Oxford University Press, Oxford.
23. Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1993;1945-1951.
24. 1H NMR studies of gossypol and its complexes with some organic compounds. J. Mol. Struct. 220:1990;261-268.
25. 31P nuclear magnetic resonance and toxicity studies. Cancer Res. 50:1990;6936-6943.
26. 31P-magnetic resonance spectroscopy and in vitro antimitochondrial tumour toxicity with gossypol and rhodamine-123. J. Clin. Invest. 79:1987;517.
27. Tanphaichitr N., Fitzgerald L.M. Incorporation of gossypol and formation of its protein conjugates in mouse transformed Sertoli (TM4) cells. J. Androl. 10:1989;195-201.
28. Benz C.C., Keniry M.A., Ford J.M., Townsend A.J., Cox F.W., Palayoor S, Matlin S.A., Hait W.N., Cowan K.H. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol. Pharmacol. 37:1990;840-847.
29. Gilbert N.E, O'Reilly J., Change G., Lin C.Y., Brueggemeier R.W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 57:1995;61-67.
30. Pinguet F., Martel P., Fabbro M., Petit I., Canal P., Culine S., Astre C., Bressolle F. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res. 17:1997;605-611.
31. Newman E.M., Carrol M., Akman S.A., Cow W., Coluzzi P., Hamasaki V., et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumours. Cancer Chemother. Pharmacol. 39:1997;254-258.
32. Breithaupt H., Dammann A., Aiger K. Pharmacokinetics of dacarbazine and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Cancer Chemother. Pharmacol. 9:1982;103-109.
33. Fish R.G., Shelley M.D., Badman J., Mason M., Adams M., Paterson I. Platinum accumulation in adult cancer patients receiving cisplatin: Plasma and urinary platinum concentrations on first exposure. Drug Invest. 7:1994;175-182.
34. Schuler U., Schroer S., Kuhnle A., Blanz J., Mewes K., Kumbier I., Proksch B., Zeller K.P., Ehninger G. Busulphan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant. 14:1994;759-765.
35. Alberts D., Bachur N.R., Holtzman J.L. The pharmacokinetics of daunomycin in man. Clin. Pharmacol. Ther. 12:1971;96-104.
36. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27:1997;1-20.
37. Teng C.S. Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity. Contraception. 52:1995;389-395.
38. Jarvis W.D., Turner A.J., Povirk L.F., Traylor R.S., Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promeylocytic leukaemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. 54:1994;1707-1714.
39. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle differences in susceptibility of HL-60 cells to apoptosis induced by various antitumour agents. Cancer Res. 53:1993;3186-3192.